Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H1 2018

  • ID: 4482759
  • Drug Pipelines
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Epigen Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Ono Pharmaceutical Co Ltd
  • RxBio Inc
  • Ube Industries Ltd
  • MORE
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H1 2018

Summary:

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

The latest report Lysophosphatidic Acid Receptor 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Male Health, Metabolic Disorders, Oncology and Toxicology which include indications Pulmonary Fibrosis, Benign Prostatic Hyperplasia, Diabetic Neuropathy, Diarrhea, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome).

Furthermore, this report also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Epigen Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Ono Pharmaceutical Co Ltd
  • RxBio Inc
  • Ube Industries Ltd
  • MORE
Introduction

Report Coverage

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Epigen Biosciences Inc

F. Hoffmann-La Roche Ltd

Ono Pharmaceutical Co Ltd

RxBio Inc

Ube Industries Ltd

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles

BMS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7300243 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rx-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UD-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones

Featured News & Press Releases

Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation

May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society

May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM

Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis

Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM

Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Epigen Biosciences Inc, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Pipeline by RxBio Inc, H1 2018

Pipeline by Ube Industries Ltd, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bristol-Myers Squibb Co
  • Epigen Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Ono Pharmaceutical Co Ltd
  • RxBio Inc
  • Ube Industries Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll